Kura Oncology, Inc. (KURA) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-05

How it makes money

It earns revenue when medical providers prescribe its only approved drug, KOMZIFTI, to patients with specific genetic mutations in acute myeloid leukemia.

Profitability depends on the adoption of KOMZIFTI by oncologists and the willingness of third-party payors, such as insurance companies and Medicare, to provide reimbursement. Revenue is driven by the number of patients diagnosed with relapsed or refractory AML possessing the NPM1 mutation, the duration of their treatment, and the drug's price relative to alternative standards of care.

What protects it: the moat

It relies on FDA-granted regulatory exclusivity and its proprietary patent portfolio to prevent competitors from selling generic or biosimilar versions of its treatments.

Management claims that KOMZIFTI holds a competitive advantage because it is the first and only menin inhibitor approved for once-daily oral administration, which simplifies treatment compared to other options. It further asserts that its intellectual property and ongoing research into companion diagnostics create barriers to entry by ensuring the drug is used specifically in patients most likely to respond.

What growth costs

It must heavily reinvest in R&D and clinical trials to expand its drug indications and secure its position as a foundational combination therapy.

The company spends significantly on registrational Phase 3 clinical trials to prove efficacy when combining its drugs with existing chemotherapy standards. Additionally, it incurs costs to build a commercial infrastructure, manage patient access programs, and conduct post-marketing studies mandated by the FDA as a condition of its drug approval.

What could damage it

If clinical data from ongoing trials shows safety issues or lack of efficacy in broader patient groups, regulatory bodies could restrict the drug's label.

A mandatory label restriction or a negative safety finding would directly impair the company’s ability to market the drug, leading to a loss of coverage by insurance payors. Because the company currently lacks revenue diversity, any limitation on the usage of its single approved product would cause a total collapse of its primary earnings stream.

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Other companies in Biotechnology